Corindus Vascular Robotics Inc.05.15.17
Corindus Vascular Robotics Inc. has announced the milestone of the 100th robotic-assisted percutaneous coronary intervention (PCI) case performed using its second-generation CorPath GRX System. Since its commercial launch in January 2017, the CorPath GRX System has been used in a variety of procedural settings and physicians have reported an increase in the number of procedures that can be performed robotically.
"The CorPath GRX System is an important advancement in the field of interventional cardiology and I am pleased to be a part of the initial launch of this enhanced technology. The addition of active guide management has allowed me to increase the number of interventional procedures I perform robotically, and as a result, I was able to complete several difficult cases entirely using the CorPath GRX System," said Sunil Rao, M.D., section chief of Cardiology at the Durham, Va., Medical Center.
The CorPath GRX System offers improvements in procedural control, enhanced workflow and radiation protection for physicians, patients and staff. Since its commercial launch, the CorPath GRX System has been used successfully in a variety of PCI cases including complex multi-vessel disease, NSTEMI, left radial access, diffused and calcified lesions, FFR, ostial RCA and subtotal 99 percent occlusions.
"The completion of the first 100 cases using our CorPath GRX System represents a significant milestone for Corindus," said Mark Toland, president and CEO of Corindus. "The early feedback from our customers has been positive and we are excited to continue our U.S. commercial roll-out throughout the rest of this year."
Corindus Vascular Robotics Inc. develops robotic-assisted vascular interventions. The company's CorPath System is the first U.S. Food and Drug Administration-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. The company is based in Waltham, Mass.
"The CorPath GRX System is an important advancement in the field of interventional cardiology and I am pleased to be a part of the initial launch of this enhanced technology. The addition of active guide management has allowed me to increase the number of interventional procedures I perform robotically, and as a result, I was able to complete several difficult cases entirely using the CorPath GRX System," said Sunil Rao, M.D., section chief of Cardiology at the Durham, Va., Medical Center.
The CorPath GRX System offers improvements in procedural control, enhanced workflow and radiation protection for physicians, patients and staff. Since its commercial launch, the CorPath GRX System has been used successfully in a variety of PCI cases including complex multi-vessel disease, NSTEMI, left radial access, diffused and calcified lesions, FFR, ostial RCA and subtotal 99 percent occlusions.
"The completion of the first 100 cases using our CorPath GRX System represents a significant milestone for Corindus," said Mark Toland, president and CEO of Corindus. "The early feedback from our customers has been positive and we are excited to continue our U.S. commercial roll-out throughout the rest of this year."
Corindus Vascular Robotics Inc. develops robotic-assisted vascular interventions. The company's CorPath System is the first U.S. Food and Drug Administration-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. The company is based in Waltham, Mass.
